Bruce Levine, PhD, graduated with a BA from the University of Pennsylvania in 1984 and continued his education at The Johns Hopkins University where he obtained his PhD in immunology and infectious disease in 1992. Prof. Levine further trained as a post-graduate fellow at the Henry M. Jackson Foundation, Naval Medical Research Institute, National Naval Medical Center in Bethesda, MD.
Prof. Levine has won many awards including the “The Medicine Maker” Power List in 2020, Society for the Immunotherapy of Cancer Team Science Award and more. He is an active member in many professional organizations including American Society for Gene and Cell Therapy and a reviewer for the International Society for Cellular Therapy Annual Meeting, amongst others.
Speaking on immunology, cell and gene therapy
Prof. Levine’s research interests focus on lymphocyte growth, activation and senescence, and its application in gene therapy through clinical trials. He has co-invented and co-authored over 20 US patents and 140 publications. His work on re-purposing T-lymphocytes from HIV+ patients and cancer patients for improving the immune response has been approved by the FDA as a gene therapy.